While more research is needed, experts consider semaglutide a promising development in addressing alcohol addiction.
There are early and suggestive data that GLP-1 drugs reduce alcohol cravings. A large cohort of people with alcohol use ...
The Maryland-based biopharma joins Eli Lilly and Novo Nordisk in trialing a GLP-1 agonist for alcohol- and liver-related ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results